Loading
Oncology has two respected scales that grade how much a drug helps in each indication; payers could set low copays for high-grade uses and require a conversation for low-grade ones instead of blanket prior authorisation.
The ESMO Magnitude of Clinical Benefit Scale grades each indication from 1 to 5 (palliative) or A to C (curative); the ASCO Value Framework produces a net health benefit score; ICER publishes cost-effectiveness reviews. Value-based insurance design lowers cost sharing for high-value care. Applying the scales to oncology formularies (zero copay for ESMO-MCBS 4 and 5 indications, standard review for 1 and 2) would target scrutiny where benefit is smallest and remove it where the case is clear, without any payer inventing its own scoring.
Shares ICER and health technology assessment, European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains, Prices and value.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains, Prices and value.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.